Director of Clinical Pharmacology
Gilead Sciences, Inc., Foster City, CA, USA
Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)
Gilead Sciences: Director of Clinical Pharmacology, Jan 2023 – present
• Leading clinical pharmacology studies of the highest complexity. Provide strategic and scientific leadership for the clinical pharmacology program of new compounds in virology, including pediatric development.
Innovent Biologics: Director of Clinical Pharmacology, Dec 2021 – Nov 2022
• Leading strategic, scientific and operational aspects of 10+ assets (mainly immuno-oncology assets) from a clinical pharmacology perspective.
Division of Inflammation and Immune Pharmacology (DIIP), Office of Clinical Pharmacology (OCP), U.S. FDA: Clinical Pharmacology & Pharmacometrics Reviewer, Dec 2016 – Dec 2021
• Responsible for review of regulatory data submitted in INDs, NDAs, BLAs and post-approval supplements in multiple therapeutic areas, including rheumatology, pulmonary, endocrinology products and COVID-19.
University of Maryland, School of Pharmacy, Center for Translational Medicine: Postdoc fellow, Aug, 2014-Dec, 2016
• Extensive population PK modelling and simulation to support dose finding of new drugs in oncology, anti-infective disease and neurology